Effective Extracellular Payload Release and Immunomodulatory Interactions govern the Therapeutic Effect of Trastuzumab Deruxtecan (T-DXd)

Immunohistochemistry assessment of tumor infiltrating T cells levels and spatial location. CD8+ (brown), CD4+ (blue) and FoxP3+ (red). Tumors were from HER2 oncogene driven transgenic mice, and treatment were administered weekly for 4 weeks, 5.4mg/kg control IgG1, 5.4mg/kg T-DXd, and 15mg/kg anti-CD...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Zachary Hartman (20752724) (author)
مؤلفون آخرون:	Li-Chung Tsao (20752727) (author), John Wang (20752730) (author), Xingru Ma (20752733) (author), Sirajbir Sodhi (20752736) (author), Joey Ragusa (20752739) (author), Bushanqing Liu (20752742) (author), Jason McBane (20752745) (author), Tao Wang (20752748) (author), Junping Wei (20752751) (author), Cong-Xiao Liu (20752754) (author), Xiao Yang (20752757) (author), Gangjun Lei (20752760) (author), Ivan Spasojevic (20752763) (author), Ping Fan (20752766) (author), Timothy Trotter (20752769) (author), Michael Morse (20752772) (author), Herbert Lyerly (20752775) (author)
منشور في:	2025
الموضوعات:	Tumour Immunology T-DXd breast cancer HER2 antibody-drug-conjugates
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Effective Extracellular Payload Release and Immunomodulatory Interactions govern the Therapeutic Effect of Trastuzumab Deruxtecan (T-DXd)

مواد مشابهة